Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Doctors prescribe Wegovy for people with obesity or overweight ... It has Food and Drug Administration (FDA) approval for weight management. It helps prevent the intestines from absorbing around ...

In addition to voluntary pledges, WHO member states last year approved an increase in assessed contributions. This year also, ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

The United States and China announced this morning that they ... lost roughly 50 percent more weight than people who took Wegovy, per The Associated Press. It could significantly cut Medicaid ...

Lilly disclosed the initial weight loss results last December. Novo noted that Wegovy is approved to help prevent strokes and heart attacks, saying in a statement that “obesity is about more ...

WEIGHTWATCHERS CEO SIMA SISTANI OUT IN ABRUPT EXIT, EMBRACED WEIGHT LOSS DRUGS Novo Nordisk's Wegovy, approved by the FDA for chronic weight management in 2021, was the first time a single ...

"The highest dose of tirzepatide is five times higher than the approved maximum doses of semaglutide," said Novo Nordisk adding that in the trial, the among of weight loss for Wegovy was lower ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors ...